Mangoceuticals Inc (MGRX)
NASDAQHealth CareMedical - Healthcare Information ServicesSnapshot 2026-09-04
$0.41+5.30%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - Healthcare Information ServicesSnapshot 2026-09-04
QuarterlyIQ Insights · MGRX
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 110.1% |
| Our one-year growth estimate | diamond | Not available |
Growth built into the price is above our model estimate.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
Model as of — · Company calendar date is not available
MGRX — M&A activity — Termination of a Material Definitive Agreement
Dated 2026-08-21
Termination of a Material Definitive Agreement. Termination of Business Combination Agreement with Nuclea Energy Inc. On August 19, 2026, Mangoceuticals, Inc. (the “Company” or “MGRX”) and Nuclea Energy Inc. (“Nuclea”) mutually agreed to terminate that certain Business Combination Agreement, dated as of July 29, 2026 (the “BCA”), among the Company, Nuclea, and the Principal Nuclea Shareholders and Mango Principals party thereto, pursuant to Section 12.1(a) of the BCA. The BCA contemplated a s…
Why it matters: Meeting the $1.00 per share requirement is crucial for maintaining the Nasdaq listing.
Worry ifMangoceuticals' share price goes above $1.00. It stays there for 10 trading days.
Less concerning ifShare price remains below $1.00 for 10 consecutive trading days.
Why it matters: If healthcare sector growth speeds up, it could benefit Mangoceuticals.
Supportive ifHealthcare sector revenue growth is speeding up again. It may reach 10% or more.
Worry ifSector growth keeps slowing down below current levels.
Why it matters: Improved revenue from TRT would show progress in Mangoceuticals' main growth area.
Supportive ifQ2 revenue from TRT shows an increase from $67,864 in Q1 2026.
Worry ifQ2 revenue from TRT declines or stays below $67,864.
Why it matters: Approval is needed to lift the 19.99% share cap for the Nuclea deal. This is crucial for moving forward.
Supportive ifStockholders approve the deal. This lets Mangoceuticals issue more shares than planned.
Worry ifStockholders reject the transaction, keeping the share cap in place.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$472 on $10,000 · ±4.7% | How much price usually moves either way. |
| Bad day | $1,397 loss on $10,000 · 14.0% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $9,409 loss on $10,000 · 94.1% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: This report will show Mangoceuticals' financial health and key goals.
Watch forThe earnings report shows more revenue and fewer losses than before.
Also watch forThe earnings report shows less revenue and more losses.
Why it matters: The company faces a compliance issue. A successful update would show progress.
Supportive ifA public announcement shows compliance with the $1.00 per share rule.
Worry ifNo update or a bad update about Nasdaq compliance.
Why it matters: Mangoceuticals must meet the $1.00 bid price for 10 days to stay listed. Failure could lead to delisting.
Worry ifThe stock maintains a closing bid price of at least $1.00 for 10 consecutive business days.
Less concerning ifThe stock fails to reach the $1.00 bid price before the deadline.
Why it matters: This deal could help Mangoceuticals grow in the nuclear field. Problems could hurt investor trust.
Supportive ifLook for news on approvals or progress with Nuclea Energy.
Worry ifWatch for delays or the end of the deal.
Why it matters: Better operating income shows stronger finances and may bring in more investors. Ongoing losses could worry people.
Supportive ifOperating income shows a smaller loss than last quarter, which is a good sign.
Worry ifOperating income gets worse or stays at a big loss.